After 12 weeks , reduction in mean uNTX and CTX on everolimus plus zoledronic acid relative to everolimus was 68.4 % ( 95 % CI , 60.1 % -74.9 % ; P < .0001 ) and 76.2 % ( 95 % CI , 67.3 % -82.7 % ; P < .0001 ) , respectively .